表紙
市場調査レポート

Cosmo Pharmaceuticals S.p.A - 製品パイプライン分析

Cosmo Pharmaceuticals S.p.A - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 192539
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Cosmo Pharmaceuticals S.p.A - 製品パイプライン分析 Cosmo Pharmaceuticals S.p.A - Product Pipeline Review - 2015
出版日: 2015年09月09日 ページ情報: 英文 42 Pages
概要

Cosmo Pharmaceuticals S.p.A はルクセンブルクに本社を置く製薬企業で、消化器疾患治療薬の開発・製造・販売を行っています。また、委託契約生産、医薬品安定性評価、製造工程評価、臨床試験のための試薬準備などのサービスも提供しています。

当レポートでは、Cosmo Pharmaceuticals S.p.Aにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Cosmo Pharmaceuticals S.p.A の基本情報

  • Cosmo Pharmaceuticals S.p.A の概要
  • 主要情報
  • 企業情報

Cosmo Pharmaceuticals S.p.A :R&Dの概要

  • 主な治療範囲

Cosmo Pharmaceuticals S.p.A :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Cosmo Pharmaceuticals S.p.A :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
    • 第?相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
  • 開発段階が不明なパイプライン製品
    • 開発段階が不明な製品/併用療法モダリティ

Cosmo Pharmaceuticals S.p.A :薬剤プロファイル

  • mesalamine ER
  • rifamycin
  • AS-101
  • budesonide ER
  • CB-0604
  • naloxone hydrochloride
  • CB-0112

Cosmo Pharmaceuticals S.p.A :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Cosmo Pharmaceuticals S.p.A :最新のパイプライン情報

Cosmo Pharmaceuticals S.p.A :開発休止中のプロジェクト

Cosmo Pharmaceuticals S.p.A :開発が中止された製品

  • 開発が中止された製品のプロファイル

Cosmo Pharmaceuticals S.p.A :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07561CDB

Summary

Global Markets Direct's, 'Cosmo Pharmaceuticals S.p.A - Product Pipeline Review - 2015', provides an overview of the Cosmo Pharmaceuticals S.p.A's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cosmo Pharmaceuticals S.p.A's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cosmo Pharmaceuticals S.p.A including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cosmo Pharmaceuticals S.p.A's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cosmo Pharmaceuticals S.p.A's pipeline products

Reasons to buy

  • Evaluate Cosmo Pharmaceuticals S.p.A's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cosmo Pharmaceuticals S.p.A in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cosmo Pharmaceuticals S.p.A's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cosmo Pharmaceuticals S.p.A and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cosmo Pharmaceuticals S.p.A
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cosmo Pharmaceuticals S.p.A and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cosmo Pharmaceuticals S.p.A Snapshot
    • Cosmo Pharmaceuticals S.p.A Overview
    • Key Information
    • Key Facts
  • Cosmo Pharmaceuticals S.p.A - Research and Development Overview
    • Key Therapeutic Areas
  • Cosmo Pharmaceuticals S.p.A - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Cosmo Pharmaceuticals S.p.A - Pipeline Products Glance
    • Cosmo Pharmaceuticals S.p.A - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Cosmo Pharmaceuticals S.p.A - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Cosmo Pharmaceuticals S.p.A - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Cosmo Pharmaceuticals S.p.A - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Cosmo Pharmaceuticals S.p.A - Drug Profiles
    • mesalamine ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rifamycin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AS-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • budesonide ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-0604
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • naloxone hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-0112
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cosmo Pharmaceuticals S.p.A - Pipeline Analysis
    • Cosmo Pharmaceuticals S.p.A - Pipeline Products by Target
    • Cosmo Pharmaceuticals S.p.A - Pipeline Products by Route of Administration
    • Cosmo Pharmaceuticals S.p.A - Pipeline Products by Molecule Type
    • Cosmo Pharmaceuticals S.p.A - Pipeline Products by Mechanism of Action
  • Cosmo Pharmaceuticals S.p.A - Recent Pipeline Updates
  • Cosmo Pharmaceuticals S.p.A - Dormant Projects
  • Cosmo Pharmaceuticals S.p.A - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • mesalamine ER
  • Cosmo Pharmaceuticals S.p.A - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cosmo Pharmaceuticals S.p.A, Key Information
  • Cosmo Pharmaceuticals S.p.A, Key Facts
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Indication, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Stage of Development, 2015
  • Cosmo Pharmaceuticals S.p.A - Monotherapy Products in Pipeline, 2015
  • Cosmo Pharmaceuticals S.p.A - Partnered Products in Pipeline, 2015
  • Cosmo Pharmaceuticals S.p.A - Partnered Products/ Combination Treatment Modalities, 2015
  • Cosmo Pharmaceuticals S.p.A - Out-Licensed Products in Pipeline, 2015
  • Cosmo Pharmaceuticals S.p.A - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Cosmo Pharmaceuticals S.p.A - Phase III, 2015
  • Cosmo Pharmaceuticals S.p.A - Phase II, 2015
  • Cosmo Pharmaceuticals S.p.A - Phase I, 2015
  • Cosmo Pharmaceuticals S.p.A - Preclinical, 2015
  • Cosmo Pharmaceuticals S.p.A - Unknown, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Target, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Route of Administration, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Molecule Type, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline Products by Mechanism of Action, 2015
  • Cosmo Pharmaceuticals S.p.A - Recent Pipeline Updates, 2015
  • Cosmo Pharmaceuticals S.p.A - Dormant Developmental Projects,2015
  • Cosmo Pharmaceuticals S.p.A - Discontinued Pipeline Products, 2015
  • Cosmo Pharmaceuticals S.p.A, Subsidiaries

List of Figures

  • Cosmo Pharmaceuticals S.p.A - Pipeline by Top 10 Indication, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Stage of Development, 2015
  • Cosmo Pharmaceuticals S.p.A - Monotherapy Products in Pipeline, 2015
  • Cosmo Pharmaceuticals S.p.A - Partnered Products in Pipeline, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Top 10 Target, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Top 10 Route of Administration, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Top 10 Molecule Type, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top